Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease

Marras et al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D

Detalles Bibliográficos
Autores principales: Marras, Theodore K., Hassan, Mariam, Mange, Kevin C., Ciesielska, Monika, Murthy, Shilpa Dhar, Jumadilova, Zhanna, Chatterjee, Anjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271752/
https://www.ncbi.nlm.nih.gov/pubmed/35821755
http://dx.doi.org/10.1183/23120541.00623-2021
_version_ 1784744739084435456
author Marras, Theodore K.
Hassan, Mariam
Mange, Kevin C.
Ciesielska, Monika
Murthy, Shilpa Dhar
Jumadilova, Zhanna
Chatterjee, Anjan
author_facet Marras, Theodore K.
Hassan, Mariam
Mange, Kevin C.
Ciesielska, Monika
Murthy, Shilpa Dhar
Jumadilova, Zhanna
Chatterjee, Anjan
author_sort Marras, Theodore K.
collection PubMed
description Marras et al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D
format Online
Article
Text
id pubmed-9271752
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-92717522022-07-11 Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease Marras, Theodore K. Hassan, Mariam Mange, Kevin C. Ciesielska, Monika Murthy, Shilpa Dhar Jumadilova, Zhanna Chatterjee, Anjan ERJ Open Res Research Letters Marras et al. report a low number needed to treat and high number needed to harm supporting addition of amikacin liposome inhalation suspension to guideline-based treatments in patients with treatment-refractory Mycobacterium avium complex lung disease https://bit.ly/3tPFW7D European Respiratory Society 2022-07-11 /pmc/articles/PMC9271752/ /pubmed/35821755 http://dx.doi.org/10.1183/23120541.00623-2021 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
spellingShingle Research Letters
Marras, Theodore K.
Hassan, Mariam
Mange, Kevin C.
Ciesielska, Monika
Murthy, Shilpa Dhar
Jumadilova, Zhanna
Chatterjee, Anjan
Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
title Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
title_full Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
title_fullStr Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
title_full_unstemmed Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
title_short Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
title_sort amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory mycobacterium avium complex lung disease
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271752/
https://www.ncbi.nlm.nih.gov/pubmed/35821755
http://dx.doi.org/10.1183/23120541.00623-2021
work_keys_str_mv AT marrastheodorek amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease
AT hassanmariam amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease
AT mangekevinc amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease
AT ciesielskamonika amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease
AT murthyshilpadhar amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease
AT jumadilovazhanna amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease
AT chatterjeeanjan amikacinliposomeinhalationsuspensionclinicalbenefitriskassessmentforrefractorymycobacteriumaviumcomplexlungdisease

Ejemplares similares